Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if so...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Lorena, Fanale, Daniele, Badalamenti, Giuseppe, Porta, Camillo, Olive, Daniel, De Luca, Ida, Brando, Chiara, Rizzo, Mimma, Messina, Carlo, Rediti, Mattia, Russo, Antonio, Bazan, Viviana, Iovanna, Juan Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595592/
https://www.ncbi.nlm.nih.gov/pubmed/33178494
http://dx.doi.org/10.1080/2162402X.2020.1832348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595592/
https://www.ncbi.nlm.nih.gov/pubmed/33178494
http://dx.doi.org/10.1080/2162402X.2020.1832348

Ejemplares similares